Skip to main content

Advertisement

SpringerLink
Log in

A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients

  • Commentary
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

The Original Article was published on 22 January 2014

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kansui Y, Ohtsubo T, Goto K, et al. Association of serum uric acid with blood pressure in Japanese men: cross-sectional study in work-site group. Circ J. 2011;75:2827–32.

    Article  CAS  PubMed  Google Scholar 

  2. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.

    Article  CAS  PubMed  Google Scholar 

  3. Toda A, Ishizaka Y, Tani M, et al. Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. Nephron Clin Pract. 2014;15(126):33–8.

    Article  Google Scholar 

  4. Becker MA, Schumachar HR, Wortmann RL, et al. Febuxostat compared allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.

    Article  CAS  PubMed  Google Scholar 

  5. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopirinol is common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.

    Article  PubMed  Google Scholar 

  6. Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523–6.

    Article  CAS  PubMed  Google Scholar 

  7. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008;108:69–78.

    Article  Google Scholar 

  8. Sánchez-Lozada LG, Tapia E, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23:1179–85.

    Article  PubMed  Google Scholar 

  9. Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549–56.

    Article  CAS  PubMed  Google Scholar 

  10. Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38(3):258–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan

    Masaki Ohya & Takashi Shigematsu

Authors
  1. Masaki Ohya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Ohya.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohya, M., Shigematsu, T. A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients. Clin Exp Nephrol 18, 835–836 (2014). https://doi.org/10.1007/s10157-014-0989-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-014-0989-7

Keywords

Search

Navigation